EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data

David Hodgson iD, James Hay, Sheikh Jarju, Dawda Jobe, Rhys Wenlock, Thushan I de Silva, Adam J Kucharski

PLOS Computational Biology · 2025

DOI: 10.1371/journal.pcbi.1013467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, 2025. Verfasst von David Hodgson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom. Hauptthemen laut MEDLINE: COVID-19, Antibodies, Viral, Software, COVID-19 Serological Testing. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, NIAID NIH HHS, UK Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Understanding acute infectious disease dynamics at individual and population levels is critical for informing public health preparedness and response. Serological assays, which measure a range of biomarkers relating to humoral immunity, can provide a valuable window into immune responses generated by past infections and vaccinations. However, traditional methods for interpreting serological data, such as binary seropositivity and seroconversion thresholds, often rely on heuristics that fail to account for individual variability in antibody kinetics and timing of infection, potentially leading to biased estimates of infection rates and post-exposure immune responses. To address these limitations, we developed serojump , a novel probabilistic framework and software package that uses individual-level serological data to infer infection status, timing, and subsequent antibody kinetics. We validated serojump using simulated serological data and real-world SARS-CoV-2 datasets from The Gambia. In simulation studies, the model accurately recovered individual infection status, population-level antibody kinetics, and the relationship between biomarkers and immunity against infection, demonstrating robustness under observational noise. Benchmarking against standard serological heuristics in real-world data revealed that serojump achieves higher sensitivity in identifying infections, outperforming static threshold-based methods and precision in inferred infection timing. Application of serojump to longitudinal SARS-CoV-2 serological data taken during the Delta wave provided additional insights into i) missed infections based on sub-threshold rises in antibody level and ii) antibody responses to multiple biomarkers post-vaccination and infection. Our findings highlight the utility of serojump as a pathogen-agnostic, flexible tool for serological inference, enabling deeper insights into infection dynamics, immune responses, and correlates of protection. The open-source framework offers researchers a platform for extracting information from serological datasets, with potential applications across various infectious diseases and study designs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antibodies, ViralSoftwareCOVID-19 Serological TestingHumansSARS-CoV-2Bayes TheoremLongitudinal StudiesKineticsComputational BiologyComputer SimulationBiomarkersTime Factors

Substanzen

Antibodies, ViralBiomarkers

Autor:innen und Institutionen

  • Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Charité Center for Global Health, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • Vaccines and Immunity Theme, MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, The Gambia.
  • Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.
  • Florey Institute of Infection and Sheffield NIHR Biomedical Research Centre, University of Sheffield, Sheffield, United Kingdom.

ORCID-Profile: David Hodgson

Förderung

  • Wellcome Trust
  • NIAID NIH HHS
  • UK Research and Innovation
  • National Institute of Health

Zitieren

APA

Hodgson, D., Hay, J., Jarju, S., Jobe, D., Wenlock, R., de Silva, T. I., & Kucharski, A. J. (2025). serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1013467

Vancouver

Hodgson D, Hay J, Jarju S, Jobe D, Wenlock R, de Silva TI, et al. serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data. PLOS Computational Biology. 2025. doi:10.1371/journal.pcbi.1013467

BibTeX
@article{Hodgson2025,
  author = {Hodgson, David and Hay, James and Jarju, Sheikh and Jobe, Dawda and Wenlock, Rhys and de Silva, Thushan I and Kucharski, Adam J},
  title = {serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data},
  journal = {PLOS Computational Biology},
  year = {2025},
  doi = {10.1371/journal.pcbi.1013467}
}
Kostenlos starten →